Skip to main content
Fig. 9 | World Journal of Surgical Oncology

Fig. 9

From: Identifying subgroups deriving the most benefit from PD-1 checkpoint inhibition plus chemotherapy in advanced metastatic triple-negative breast cancer: a systematic review and meta-analysis

Fig. 9

Forest plot of meta-analysis of progression-free survival (PFS) based on based on exposure to previous (A) chemotherapy and (B) taxane chemotherapy between patients receiving immunotherapy plus chemotherapy (ICT) and CT alone. Immunotherapy mainly consisted of PD-1/PD-L1 inhibitors

Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us